LOS ANGELES, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc.
(NASDAQ: RENB) (the "Company"), a biotechnology corporation focusing on cell,
gene, and immunotherapy, announced today the results of the Company's Special
Meeting of Shareholders held at 12:00 pm ET on January 25, 2024.
All of the matters put forward before the Company's shareholders for
consideration and approval, as set out in the Company's definitive proxy
statement dated January 3, 2024, were approved by the requisite number of votes
cast at the meeting.
For complete results on all matters voted on at the meeting, please consult the
Company's Form 8-K which will be filed on EDGAR at www.sec.gov/edgar
(http://www.sec.gov/edgar).
ABOUT THE COMPANY
Renovaro has developed advanced cell, gene, and immunotherapy platforms designed
to renew the body's natural tumor-fighting capabilities against cancer and
infectious diseases. For more information on Renovaro, go to their website at
www.renovarobio.com.
Contact: ir@renovarobio.com
Source: Renovaro Bioscience Inc.
Â